Company Overview
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Recent Developments
- Dec 2025 Revenue of $815.37K (-67.7% YoY); net profit $-14.03M.
- Trailing 12 Months Year-on-year growth — revenue -83.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -83.90% |
Stock Price Performance
| 1 Year: | -99.46% |
| 6 Months: | -96.81% |
| 3 Months: | -16.83% |
| 1 Month: | -5.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)52.68 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ONCO Onconetix, Inc. PHARMA | 0.84 | 0.00 | $3.68M | 0.00% | -40.18% | -105.23% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 704.85K | 406.86K | - | 101.63K | 106.49K | 303.65K | 303.60K | 21.46K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.80K | 35.99K | 34.76K | 55.91K | 23.11K |
| Gross Profit | - | - | - | - | - | - | - | - | - | 189.00K | 100.72K | 105.41K | - | 45.83K | 70.50K | 268.89K | 247.68K | -1.66K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.70M | 1.41M | 2.34M | 1.53M | 2.09M |
| Operating Income | -325.78K | -792.27K | -1.10M | -2.07M | -4.29M | -3.87M | -2.85M | -6.65M | -4.49M | -11.08M | -13.62M | -2.65M | - | -1.65M | -1.34M | -2.07M | -1.28M | -2.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.32M | -2.15M | -8.48M | 5.68M | -4.21M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 223.59K | 223.10K | 300.07K | 4.25K | 2.24K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.55M | -2.37M | -8.78M | 5.67M | -4.21M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 525 | 0 |
| Net Income | -325.78K | -792.27K | -1.10M | -2.07M | -4.26M | -3.87M | -2.85M | -6.87M | -5.35M | -11.12M | -14.31M | -3.83M | - | -8.55M | -2.37M | -8.78M | 5.67M | -4.21M |
| Diluted EPS | - | -0.29 | -0.40 | -0.34 | -0.36 | -0.27 | -0.18 | -0.43 | -12.21 | -20.08 | -2,191.59 | -249.08 | - | -2,272.50 | -238.00 | -312.50 | - | -67.10 |
| R&D Expense | 88.24K | 529.54K | 269.93K | 455.09K | 1.29M | 1.18M | 1.08M | 846.85K | 219.24K | 48.96K | - | 109.36K | - | 24.45K | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 58.47K | 2.52M | 815.37K |
| Cost of Revenue | - | 0 | 1.19M | 1.47M | 182.46K |
| Gross Profit | - | 0 | -1.13M | 1.06M | 632.91K |
| Operating Expenses | - | 13.48M | 16.72M | 11.39M | 6.98M |
| Operating Income | - | -13.48M | -17.85M | -10.33M | -6.34M |
| EBITDA | - | -13.41M | -36.71M | -57.60M | -13.27M |
| Interest Expense | - | 0 | 671.62K | 1.41M | 751.00K |
| Pretax Income | - | -13.42M | -37.42M | -59.74M | -14.03M |
| Tax Provision | - | 0 | -12.59K | -1.05M | 525 |
| Net Income | - | -13.42M | -37.41M | -58.69M | -14.03M |
| Diluted EPS | - | -151,867.29 | -285,570.18 | -21,301.06 | -828.00 |
| R&D Expense | 1.33M | 4.13M | 1.95M | 154.36K | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 26.31M | 87.52M | 28.18M | 24.93M |
| Current Assets | - | - | 26.26M | 5.84M | 950.27K | 6.07M |
| Cash & Equivalents | - | - | 25.75M | 4.55M | 646.50K | 5.22M |
| Inventory | - | - | 0 | 364.05K | 64.08K | 149.96K |
| Receivables | - | - | 0 | 149.73K | 25.72K | 296.87K |
| Total Liabilities | - | - | 3.92M | 86.11M | 18.57M | 9.16M |
| Current Liabilities | - | - | 3.92M | 17.19M | 18.29M | 9.14M |
| Long Term Debt | - | - | - | 118.86K | - | - |
| Total Debt | - | - | 0 | 9.89M | 9.45M | 48.77K |
| Total Equity | 4.73M | - | 22.39M | -5.60M | 9.61M | 15.77M |
| Shares Outstanding | - | - | 91 | 134 | 2.77K | 31.20K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -8.68M | -13.58M | -10.50M | -9.68M |
| Investing Cash Flow | - | -32.66K | -8.65M | -28.47K | 0 |
| Financing Cash Flow | - | 32.53M | 1.04M | 6.74M | 14.45M |
| Capital Expenditure | -1.92K | -9.34K | -55.04K | -28.47K | - |
| Free Cash Flow | - | -8.68M | -13.64M | -10.52M | -9.68M |
| Net Change in Cash | - | 23.82M | -21.19M | -3.78M | 4.77M |
| Share Buybacks | - | 566.81K | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | -1,927.9% | 41.8% | 77.6% |
| Operating Margin % | - | - | -30,526.4% | -409.3% | -778.2% |
| Net Margin % | - | - | -63,986.5% | -2,325.2% | -1,721.0% |
| ROE % | - | -59.9% | 667.8% | -610.7% | -89.0% |
| ROCE % | - | -60.2% | -25.4% | -104.4% | -40.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 1.17% | 51.40K | $32.84K |
| 2 | Xtx Topco Ltd | 0.31% | 13.55K | $8.66K |
| 3 | SBI Securities Co., Ltd. | 0.01% | 252 | $161 |
| 4 | Tower Research Capital LLC (TRC) | - | 145 | $92 |
| 5 | Hollencrest Capital Management | - | 100 | $63 |
| 6 | Morgan Stanley | - | 21 | $13 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ONCO
Onconetix Inc (ONCO) Stock Price, Quote, News & History - Benzinga
<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTE9BcV9JQVJYbVlGRDhqWjNHai00am1HTnN3UV9mLXRVVWFaVC1PTEg3eWlwQjVrdXBGWFQtUGdfOHZVM052b253bW1lNA?oc=5" target="_blank">Onconetix Inc (ONCO) Stock Price, Quote, News & History</a> …
Post-Market Losers: Notable After-Hours Decliners - ChartMill
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQOUxoUmp3cDZtemJDczMtU0o4TVBaRDVzUy1fWS1CR3ptTlhtR2hza0pvLVV6RVg3ZXdWTHoyODNhRWtQd0plNS1LMUlyTTJaZExfLXFpczRUWjhsQU5tR0RRZ1JuQXRlMnI1azByWG5DUzk1VTMxSnN6TFhSc3pmaFk1WDZsc1ZpYlliRE…
Onconetix, Inc. SEC Filing (Sep 4, 2026) | ONCO EFFECT - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQT0N6SVJ0Z3k0VlhYTm1fcFlaYmpPZEJoU2FfUUNpRGtlMVcyMU1vM3pvci1LXzVmVEpHYTBTcHNEcVpuckFOb0VHSEowcUhCNU1XUzJXUjFzRmpVTDVkZkwtelFfNFZWTDlEWVpmQks1dmRKeFpTQzhmZmkyMkNpSHZMSlRnN0tUYzBqSk…
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPR1pKemZaU2RCc3lpTUVnN1NmVkhhdUxLUGw1eUZqVVpRNndTWUdoanJSYjc1b0lHWW1jd1JZNE1zOVhsdnZTeGstdGFXeDlsWUNHSm44OTBSZ1djX0pLejdTYmZiTllCeUJMbllBUjBTUThFQ0tVLVdJdmpjT3U4bzU2d2FNMnM5ZWdpRU…
$ONCO stock is up 15% today. Here's what we see in our data. | ONCO Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPU21kSkZnWUw0S3hlVUFmUUR6MkFYS19Xd3ZpOURzMWRwMjdtRE5fTl9uYVFCbGpiREhnZTI1S0NuWE0xNnNyQnhSNHZyRC1EejRVcFY5REluTDZ0bkpwR3dSYmUteUd2ZlV4b2VlbTJHZC1zTm1uNDRJdUFSRGlqRDZyb1ltX0NuU202Rk…
Onconetix Inc (NASDAQ: ONCO) Share Price, ONCO Stock News, ONCO Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFBMSXFSY0xHb08ybjQxNUt4bElFTkdqZDNNWExkZ1ZfUXdTUWZ2ZkJNZGdKYVlEdkJzTzgxMzFJTWdvOEFYNTJTd2xvdmtJSW1KbDh3eENn?oc=5" target="_blank">Onconetix Inc (NASDAQ: ONCO) Share Price, ONCO Stoc…
ONCO — Frequently Asked Questions
What is the current share price of Onconetix, Inc. (ONCO)?
As of 2026-09-19 21:16 PDT, Onconetix, Inc. (ONCO) trades at $0.84 on NasdaqCM. Its 52-week range is $0.61 to $206.00.
What is the market capitalisation of ONCO?
Onconetix, Inc. (ONCO) has a market capitalisation of $3.68M on NasdaqCM.
What is the return on equity (ROE) of ONCO?
ONCO has a return on equity (ROE) of -105.23%. Its return on capital employed (ROCE) is -40.18%.
Is ONCO a good stock to buy?
This page provides a data-driven analysis of Onconetix, Inc. (ONCO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.